An Analysis of a Phase II Study of Trastuzumab and Eribulin for HER2+ Metastatic Breast Cancer
Adam M. Brufsky, MD, PhD, discusses the results of a study that looked at the effect of prior trastuzumab on eribulin mesylate in combination with trastuzumab as first-line treatment for HER2-positive locally recurrent or MBC.
Clinical Pearls
Adam M. Brufsky, MD, PhD, professor of medicine, associate chief, Division of Hematology/Oncology, University of Pittsburgh, discusses the results of a phase II study that looked at the effect of prior trastuzumab on eribulin mesylate in combination with trastuzumab as first-line treatment for HER2-positive locally recurrent or metastatic breast cancer.
- Eribulin has demonstrated a survival advantage in HER2-negative metastatic breast cancer.
- In this phase II trial, 52 patients received eribulin and trastuzumab for a median treatment duration of about 30 weeks. Twenty-one patients had received prior trastuzumab.
- Objective response rates were high, regardless of treatment with prior trastuzumab (ORR = 62%) or not (ORR = 77%).
- Activity has been demonstrated in the first-line, though Brufsky anticipates there will be activity across all lines of therapy.
<<<
Survivorship Care Promotes Evidence-Based Approaches for Quality of Life and Beyond
March 21st 2025Frank J. Penedo, PhD, explains the challenges of survivorship care for patients with cancer and how he implements programs to support patients’ emotional, physical, and practical needs.
Read More
